BMJ Open

Effectiveness and safety of glibenclamide for stroke: protocol for a systematic review and meta-analysis

Lihong Wen ,[1] Bin Huang,[2] Rong Tu,[1] Kunzhen Wan,[1] Hong Zhang,[1] Xiaoyun Zhang[1]

To cite: Wen L, Huang B, Tu R, *et al*. Effectiveness and safety of glibenclamide for stroke: protocol for a systematic review and meta-analysis. *BMJ Open* 2021;**11**:e043585. doi:10.1136/bmjopen-2020-043585

► Prepublication history and supplemental material for this paper is available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2020-043585).

LW and BH contributed equally.

LW and BH are joint first authors.

Received 08 August 2020
Revised 20 February 2021
Accepted 23 February 2021

[1]Emergency Department, Chengdu University of Traditional Chinese Medicine Affiliated Hospital, Chengdu, China
[2]General Practice Department, Chengdu University of Traditional Chinese Medicine Affiliated Hospital, Chengdu, Sichuan, China

Correspondence to
Xiaoyun Zhang;
zhangxy1980@126.com and Hong Zhang;
30380997@qq.com

ABSTRACT

Introduction Despite the continuous improvement in modern medical treatment, stroke is still a leading cause of death and disability worldwide. How to effectively improve the survival rate and reduce disability in patients who had a stroke has become the focus of many investigations. Recent findings concerning the benefits of glibenclamide as a neuroprotective drug have initiated a new area for prospective studies on the effects of sulfonylureas. Given the high mortality and disability associated with stroke, it is essential to weigh the benefits of neuroprotective drugs against their safety. Therefore, the objective of the current study is to conduct a systematic review using meta-analysis to assess the benefits and safety of glibenclamide as a neuroprotective drug.

Methods and analysis This study will analyse randomised clinical trials (RCTs) and observational studies published up to 31 December 2020 and include direct or indirect evidence. Studies will be retrieved by searching PubMed, EMBASE, Web of Science, the Cochrane Library and China National Knowledge Infrastructure (CNKI) and WanFang Databases. The outcomes of this study will be mortality, scores from the Modified Rankin Scale and the occurrence of hypoglycaemic events. The risk of bias will be assessed using the Cochrane risk of bias assessment instrument for RCTs. A random-effect/fixed-effect model will be used to summarise the estimates of the mean difference/risk ratio using a 95% CI.

Ethics and dissemination This meta-analysis is a secondary research project, which is based on previously published data. Therefore, ethical approval and informed consent were not required for this meta-analysis. The results of this study will be submitted to a peer-reviewed journal for publication.

PROSPERO registration number CRD42020144674.

Strengths and limitations of this study

- This is the first systematic review and meta-analysis to analyse the benefits and safety of glibenclamide in patients who had a stroke based on data from both randomised clinical trials and observational studies.
- As is common with most meta-analyses, significant and unexplained heterogeneity may exist.
- The risk for ecological fallacy exists in this study as for any aggregate data meta-analysis.

INTRODUCTION

Rationale

Stroke is a common disease with high mortality and morbidity worldwide and often leaves survivors with severe neurological impairments and long-term disability.[1 2] According to data from The Third Cause of Death Survey in China, stroke is the leading cause of mortality and disability in adults in China. The stroke burden in China currently exhibits an explosive growth trend, which is characterised by rapid increases in stroke in low-income and younger individuals.[3] At present, the average incidence for the first stroke for residents in China aged 40–74 years has increased by an annual rate of 8.3%. The prevalence of stroke in adults in China aged 40 years or older has increased from 1.89% in 2012 to 2.19% in 2016, and it is estimated that 1.96 million people die due to the consequences of stroke every year.[4] Better prevention and treatment of stroke still face enormous challenges, and the medical system needs further improvement and optimisation. Therapies targeting the underlying pathophysiology of central nervous system (CNS) ischaemia and haemorrhage are conspicuously lacking. Several neuroprotective agents have been studied, but their clinical efficacy has been unsatisfactory.

Recent findings concerning the benefits of glibenclamide (GBC) as a neuroprotective drug have initiated a number of new prospective studies.[5] GBC is a member of the sulfonylurea class of drugs and has been used in the clinic as an oral hypoglycaemic agent.[6]

It exerts its pleiotropic protective effects on acute CNS injury by inhibiting the recently characterised Sur1–Trpm4 channel (formerly, the Sur1-regulated non-selective cation (NCCa–ATP) channel). GBC improves functional neurological outcomes in stroke models by protecting the microvascular

endothelium, reducing oedema formation and secondary haemorrhage, inhibiting neuronal cell death, maintaining the integrity of the blood–brain barrier (BBB) and promoting neurogenesis by blocking the Sur1–Trpm4 channel.[7 8] Thus, GBC has received renewed attention as a CNS treatment for ischaemic and haemorrhagic stroke and subarachnoid haemorrhage.[9–13] When studied in models of ischaemic stroke, GBC significantly reduced the mortality rate to 5%, whereas the vehicle-treated group exhibited 67% mortality at 24 hours. Compared with a decompressive craniectomy group, GBC significantly improved neurological function.[14–16]

GBC scavenges free radicals, reduces activated caspase-3 expression, increases the Bcl-2/Bax ratio and inhibits apoptosis by blocking NCCA channels to improve functional neurological outcomes in a rat model of intracranial haemorrhage (ICH).[17 18]Also, GBC can significantly reduce BBB permeability and markers of cell injury or cell death, protect the normal junctional localisation of Zonula Occludens 1 (ZO-1) and reduce inflammation and markers of inflammation, vasogenic oedema, and caspase-3 activation to improve functional neurological outcomes after subarachnoid haemorrhage.[18]

Several retrospective studies suggest that taking a sulfonylurea drug and continuing it following an ischaemic CNS insult significantly improve outcomes, including survival, greater functional independence, lower National Institute of Health Stroke Scale/Score (NIHSS) and less haemorrhagic transformation.[14 19] Administration of a sulfonylurea drug also improved long-term cognitive function in clinically relevant models of subarachnoid haemorrhage.[18] A prospective study suggested that intravenous GBC reduced water accumulation and mass effects after large hemispheric infarctions.[20] Another prospective study suggested that oral GBC is safe in treating acute hemispheric infarctions and potentially could prevent brain oedema and subsequent severe disability and death. Two studies[8 21] have suggested that GBC reduced oedema, protected BBB integrity and improved long-term neurological deficits. Another study reported that GBC reduced oxidative stress, inhibited apoptosis and improved neurological deficits.[22] However, a recent study tested a widely used GBC dose shown to be effective in other studies (10 µg/kg loading dose followed by 200 ng/hour for up to 7 days), and the result suggested that recovery from neurological impairments was not improved by GBC and also did not improve ICH outcomes.[23] Ghasami *et al* compared the use of GBC and insulin when given to patients with diabetes who had a haemorrhagic stroke and reported that GBC had no benefit compared with the insulin group.[24] However, we note that this was a small, non-randomised, non-placebo-controlled trial. Thus, further clinical work in haemorrhage is needed.

Objective

The primary objective of this study is to conduct a systematic review and meta-analysis of randomised clinical trials (RCTs) and observational studies to assess the safety and efficacy of GBC as a component of the medical treatment for patients who had a stroke and develop supporting evidence for effective clinical strategies.

METHODS

Study registration

This protocol is being conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[25] or meta-analyses of healthcare interventions. The protocol report for this study follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) .[26] The PRISMA-P checklist is presented in online supplemental appendix 1.

Patient and public involvement statement

No patient involved.

Eligibility criteria

Studies meeting the following criteria will be included in the analysis: (1) RCTs and observational studies; (2) patients diagnosed with stroke using CT and MRI, including ischaemic and haemorrhagic stroke and subarachnoid haemorrhage; (3) an intervention group that will be treated with intravenous or oral GBC; (4) a comparison control group that will be included in the randomised trials, which will consist of a placebo, blank or others; (5) data concerning mortality and other major adverse events; and (6) studies published up to 31 December 2020.

Direct comparisons will be made from the identified studies that include a placebo or other control compounds. RCTs and observational studies will be screened for eligibility. Whether both types of studies should be included to conduct the meta-analysis is dependent on the circumstances because it has been suggested recently that RCTs and observational studies should not be analysed in isolation.[27] Therefore, the inclusion of selected RCTs and observational studies in the meta-analysis is dependent on the quality assessment.

Information sources

The following databases will be searched from their inception forward for potentially eligible studies without language restrictions and published up to 31 December 2020: (1) PubMed, (2) Scopus, (3) Web of Science, (4) Cochrane Central Register of Controlled Clinical Trials, and (5) CNKI and WanFang Databases. We also will manually search references from relevant randomised clinical trials identified through systematic reviews, meta-analyses and studies included in this review.

Search strategy

A systematic search of six public domain databases mentioned above will be performed. The first author will conduct all database searches without language restrictions. The search strategies will be adapted from previous research and developed using text words and medical

subject headings. We will use exploded medical subject headings and appropriate corresponding keywords related to the population, combined with exposure and outcomes, such as 'Stroke' OR 'intracerebral hemorrhage' OR 'ischemic Stroke' OR 'cerebral infarction' OR 'Hemorrhagic stroke' OR 'subarachnoid hemorrhage' AND 'Glibenclamide' AND 'prognostic' OR 'modified Rankin Scale'. A sample search strategy for PubMed is shown in online supplemental appendix 2.

Study records

Study selection

All studies will be extracted from electronic databases using the search strategy described above and imported into EndNote V.X7 software (Thomson Reuters, Canada). Duplicate studies will be removed. Two authors will select studies independent of each other. Complete articles will be retrieved for all titles and abstracts that appear to meet the inclusion criteria or where any uncertainty exists. The two reviewers (LW and BH) will list all the studies to be included and document the primary reasons for excluding studies that do not conform to the inclusion criteria. Disagreements between the two authors will be resolved by discussing with the third author (RT) and, if necessary, consulting with the fourth author (KW). The overall agreement rate prior to correcting for discrepancies will be calculated using Cohen's kappa (κ) statistics. A flow diagram will be constructed that depicts the search process. An online supplemental file containing a reference list of all excluded studies, including the reason(s) for exclusion, will be included in the study. We will show the details of the selection process in the PRISMA flow chart. The proposed structure for the flow diagram is shown in figure 1.[26]

Data acquisition

Before initiating data acquisition, a codebook will be developed in Microsoft Excel 2013. Two independent researchers will extract data. The following data will be extracted from each eligible study using a standardised data collection form: (1) study characteristics, including publication year, author, country of the study, type of study (RCT, cohort, case–control and others), sample size, follow-up duration and others; (2) participant characteristics, including age, sex, stroke type (ischaemic or haemorrhagic stroke or subarachnoid haemorrhage) and baseline condition of participants (eg, disease severity: NIHSS will be used to gauge disease severity); (3) intervention characteristics, including name of the drug(s), dose, route of administration and others; (4) control characteristics, including the type of drug(s) used, dose, route of administration and others; and (5) outcome data for mortality, Modified Rankin Scale (mRS) and occurrence of hypoglycaemic events. The first two authors will acquire the data from the selected studies, independent of each other, using the codebook in Microsoft Excel. After data acquisition, both authors will review the codebooks and resolve discrepancies by consensus. If a consensus cannot be reached, the third author will



Figure 1 Flow diagram of study selection process.

Table 1 Covariates that will be included in the study.

Studies characteristics	Publication year, author, country of the study, type of study (randomised clinical trial, cohort, case–control and others), sample size, follow-up duration and others
Participant characteristics	Age, sex, stroke type (ischaemic or haemorrhagic stroke or subarachnoid haemorrhage) and baseline condition of participants (eg, underlying disease and medication history)
Intervention characteristics	Name of the drug, dose, and route of administration (oral or intravenous)
Control characteristics	Type of the drug, dose, and route of administration
Outcome	Mortality, Modified Rankin Scale and occurrence of hypoglycaemic events

provide a recommendation. A complete list of covariates that we will include is shown in table 1.

OUTCOMES

The outcomes will include mortality, mRS and the occurrence of hypoglycaemic events.

Assessment of the quality of the evidence

According to the Grading of Recommendations Assessment, Development and Evaluation, the quality of included studies will be assessed using the online guideline development tool (http://gdt.guideline-development.org/) and divided into four levels of quality: high, moderate, low and very low.[28]

Risk of bias assessment in individual studies

Risk of bias for RCTs will be assessed using the Cochrane risk of bias instrument[29], which contains seven specific domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other biases. This instrument assesses the methodological quality of the RCTs concerning low risk, high risk or unclear risk of bias.[29] If any domain is scored high/low risk of bias, the study will be considered high/low risk of bias. No study will be excluded based on the results of the risk of bias assessment.[30] The first two authors will conduct all risk of bias assessments independent of each other. Then, the two authors will review the results for the risk of bias assessment and resolve any discrepancies by consensus. If a consensus cannot be reached, the third author will be consulted.

The nine-item Newcastle–Ottawa Quality Scale is widely used to assess the quality of non-randomised trials using risk evaluation for the adequacy of selection, comparability, and outcomes assessment.[31] The high-quality studies will be defined as studies with a score that is greater than or equal to six.

Data synthesis and analysis

Data synthesis

Review Manager V.5.3 (Cochrane Collaboration) and Stata V.16.0 software will be used to conduct this meta-analysis. The mean difference or standardised mean difference with 95% CIs is used to calculate continuous variables.

Assessment of heterogeneity

Statistical heterogeneity among included studies will be assessed using the χ^2 test and I^2 test. Initially, we will use a fixed-effect model for data analysis. If $I^2 > 0.5$ or $p<0.1$, this will indicate the presence of significant heterogeneity among the studies, and a random-effect model will be used without examining the probable cause for the high heterogeneity.

Subgroup analysis

If there is considerable heterogeneity and the data are sufficient, subgroup analyses will be conducted to identify potential causes for the heterogeneity. Subgroup analyses will be performed based on the type of stroke (ischaemic stroke, haemorrhagic stroke, or subarachnoid haemorrhage) and time to treatment.

Assessment of publication bias

Publication bias will be examined according to the funnel plot method. Also, Egger's test and Begg's test will be conducted to assess the publication bias quantitatively using Stata V.16.0 software.

Sensitivity analysis

We will conduct sensitivity analyses of the primary results to explore the robustness of the review conclusions, if feasible, after considering the impact of methodological quality, missing data and sample size. According to the Cochrane Handbook, when a sufficient number of original studies are included (generally more than ten trials), publication bias analysis will be performed using a funnel plot. A symmetrical funnel plot indicates low publication bias. If the funnel plot is asymmetrical, that will indicate a high risk for publication bias.

Software used for data analysis

All data will be analysed using Stata/IC for Mac V.16.0.

REGISTRATION

In accordance with the PRISMA-P, our systematic review with network meta-analysis was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 28 April 2020.

Acknowledgements We thank EditSprings for the medical editing assistance with an earlier version of the manuscript.

Contributors LW and BH drafted the manuscript. RT and KW contributed to the development of the data sources to search for relevant literature, including the search strategy, selection criteria, data extraction criteria and risk of bias assessment strategy. HZ provided statistical expertise, and XZ, BH and HZ provided content expertise on glibenclamide and stroke. All four authors read, provided feedback and approved the final manuscript.

Funding XZ was supported by the Projects in Sichuan Province, grant number 2020YFS0082.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer-reviewed.

ORCID iD

Lihong Wen http://orcid.org/0000-0001-9445-4932

REFERENCES

1 Caffes N, Kurland DB, Gerzanich V, *et al*. Glibenclamide for the treatment of ischemic and hemorrhagic stroke. *Int J Mol Sci* 2015;16:4973–84.
2 Feigin VL, Lawes CMM, Bennett DA, *et al*. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol* 2009;8:355–69.
3 Wu S, Wu B, Liu M, *et al*. Stroke in China: advances and challenges in epidemiology, prevention, and management. *Lancet Neurol* 2019;18:394–405.
4 Wang W, Jiang B, Sun H, *et al*. Prevalence, incidence, andmortality of stroke in China: results from a nationwide population-based survey of 480 687 adults[J]. *Circulation* 2017;135:759–71.
5 Kurland DB, Tosun C, Pampori A, *et al*. Glibenclamide for the treatment of acute CNS injury. *Pharmaceuticals* 2013;6:1287–303.
6 Marble A. Glibenclamide, a new sulphonylurea: Whither oral hypoglycaemic agents? *Drugs* 1971;1:109–15.
7 Jiang B, Li L, Chen Q, Chen Q, *et al*. Role of glibenclamide in brain injury after intracerebral hemorrhage. *Transl Stroke Res* 2017;8:04:183–93.
8 Xu F, Shen G, Su Z, *et al*. Glibenclamide ameliorates the disrupted blood-brain barrier in experimental intracerebral hemorrhage by inhibiting the activation of NLRP3 inflammasome. *Brain Behav* 2019;9:e01254.
9 Tosun C, Kurland DB, Mehta R, *et al*. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. *Stroke* 2013;44:3522–8.
10 Woo SK, Kwon MS, Ivanov A, *et al*. The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel. *J Biol Chem* 2013;288:3655–67.
11 Simard JM, Chen M, Tarasov KV, *et al*. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. *Nat Med* 2006;12:433–40.
12 Simard JM, Sheth KN, Kimberly WT, *et al*. Glibenclamide in cerebral ischemia and stroke. *Neurocrit Care* 2014;20:319–33.
13 Simard JM, Woo SK, Schwartzbauer GT, *et al*. Sulfonylurea receptor 1 in central nervous system injury: a focused review. *J Cereb Blood Flow Metab* 2012;32:1699–717.
14 Kunte H, Schmidt S, Eliasziw M, *et al*. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. *Stroke* 2007;38:2526–30.
15 Ortega FJ, Jolkkonen J, Mahy N, *et al*. Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia. *J Cereb Blood Flow Metab* 2013;33:356–64.
16 Wali B, Ishrat T, Atif F, *et al*. Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats. *Stroke Res Treat* 2012;2012:1–6.
17 Zhou F, Liu Y, Yang B, *et al*. Neuroprotective potential of glibenclamide is mediated by antioxidant and anti-apoptotic pathways in intracerebral hemorrhage. *Brain Res Bull* 2018;142:18–24.
18 Simard JM, Geng Z, Woo SK, *et al*. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. *J Cereb Blood Flow Metab* 2009;29:317–30.
19 Kunte H, Busch MA, Trostdorf K, *et al*. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. *Ann Neurol* 2012;72:799–806.
20 Vorasayan P, Bevers MB, Beslow LA, *et al*. Intravenous glibenclamide reduces lesional water uptake in large hemispheric infarction. *Stroke* 2019;50:11:3021–7.
21 Xu Z-M, Yuan F, Liu Y-L, *et al*. Glibenclamide attenuates blood-brain barrier disruption in adult mice after traumatic brain injury. *J Neurotrauma* 2017;34:925–33.
22 Huang K, Hu Y, Wu Y, *et al*. Exploratory analysis of oral glibenclamide in acute ischemic stroke. *Acta Neurol Scand* 2019;140:212–8.
23 Wilkinson CM, Brar PS, Balay CJ, *et al*. Glibenclamide, a Sur1-Trpm4 antagonist, does not improve outcome after collagenase-induced intracerebral hemorrhage. *PLoS One* 2019;14:e0215952.
24 Ghasami K, Rezvanfar MR, Faraji F. Impact of glibenclamide versus insulin on neurological and functional out comes of hemorrhagic stroke in diabetic patients. *Neurol Asia* 2013.
25 Liberati A, Altman DG, Tetzlaff J, *et al*. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* 2009;151:W–94.
26 Shamseer L, Moher D, Clarke M, *et al*. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647–17647.
27 Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. *BMJ* 2005;331:1064–5.
28 Puhan MA, Schünemann HJ, Murad MH, *et al*. A grade Working group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ* 2014;349:g5630.
29 Higgins JPT, Altman DG, Gøtzsche PC, *et al*. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
30 von Elm E, Altman DG, Egger M, *et al*. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007;335:806–8.
31 Wells GA, Shea B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. ??? 2014. Available: http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp [Accessed 5 Jun 2020].

Appendix 1.A sample search strategy for PubMed

Stroke	1.“Cerebrovascular Disorders”[Mesh] OR stroke*[tiab] OR poststroke*[tiab] OR cerebral vascular OR accident*[tiab] OR cva*[tiab] OR brain injur*[ti] OR apoplex*[tiab] 2.“Brain”[Mesh] OR brain*[tiab] OR cerebr*[tiab] OR cerebell*[tiab] OR intracran*[tiab] OR intracerebral*[tiab] OR vertebrobasilar*[tiab] 3.“Blood vessels”[Mesh] OR blood vessel*[tiab] OR vascular*[tiab] OR “arteries”[Mesh] OR arter*[tiab] 4.“Intracranial Aneurysm”[Mesh] OR “Intracranial Hemorrhages”[Mesh] OR “Intracranial OR Hemorrhage, Hypertensive”[Mesh] OR “Hematoma, Subdural, Intracranial”[Mesh] OR “Subarachnoid Hemorrhage”[Mesh] OR “SAH”[tiab] 5.“Hemorrhage”[Mesh] OR hemorrhag*[tiab] OR haemorrhag*[tiab] OR “hematoma” [Mesh] OR hematoma*[tiab] OR haematoma*[tiab] OR bleed*[tiab] 6.“Intracranial Embolism and Thrombosis”[Mesh] OR “Intracranial Embolism”[Mesh] OR “Vasospasm, OR Intracranial”[Mesh] OR “Ischemic Attack, Transient”[Mesh] OR “TIA”[tiab] OR “Brain Ischemia”[Mesh] 7.“Ischemia”[Mesh] OR ischemi*[tiab] OR ischaemi*[tiab] OR thrombo*[tiab] OR “embolism”[Mesh] OR emboli*[tiab] OR oclus*[tiab] 8.(#2 AND #7) OR #6 9.(((#2 OR subarachnoid*[tiab]) AND #5) OR #4) 10.#1 OR #8 OR #9
Glybenclamide	“diabetic medications” [Mesh] OR “Sulfonylurea” [Mesh] OR “Glybenclamide” [Mesh] OR “Glyburide” [Mesh] OR “Glibornuride"OR “Glibenclamide” [Mesh] OR “HB-419”[Mesh] OR “Maninil” [Mesh] OR “Adiab”[Mesh]
Type of studies	12.Randomised controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab] 13.Animals [mh] NOT humans [mh] 14.#12 and #13
	15.#10 and #11 and #14

PRISMA-P Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 **4**:1

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	☐	☐	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	☐	☐	
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	☐	☐	1
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	☐	☐	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	☐	☐	7
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	☐	☐	
Support					
Sources	5a	Indicate sources of financial or other support for the review	☐	☐	7
Sponsor	5b	Provide name for the review funder and/or sponsor	☐	☐	7
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	☐	☐	
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	☐	☐	2,3
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	☐	☐	3

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
METHODS					
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	☐	☐	4
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	☐	☐	4
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	☐	☐	4
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	☐	☐	5
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	☐	☐	5
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	☐	☐	5
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	☐	☐	
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	☐	☐	5
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	☐	☐	6
DATA					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	☐	☐	
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2, Kendall's tau)	☐	☐	6
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	☐	☐	6
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	☐	☐	
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	☐	☐	6

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	☐	☐	5